Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djaf032 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Sheng Nie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, South…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B e Antigens, Hepatitis B, Chronic, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The survival benefits of prophylactic antiviral therapy for cancer patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection who require immunosuppressive therapy (IST) remain unclear. The present study aims to evaluate the association of prophylactic antiviral therapy with all-cause and cause-specific mortality in cancer patients.
Methods
This multicenter, retrospective cohort study included cancer patients with HBeAg-negative chronic HBV infection who received IST between January 2012 and December 2022. Patients were divided into groups with or without prophylactic antiviral therapy with nucleos(t)ide analogues. The primary outcome was all-cause mortality within 1 year and secondary outcomes included cancer-related mortality, liver-related mortality, and hepatitis B virus reactivation (HBVr). Confounding factors in patients who did and did not receive antiviral prophylaxis were balanced by propensity score overlap weighting. The associations between prophylactic antiviral therapy and outcomes were assessed by Cox proportional hazards models.
Results
Of the 3677 cancer patients deemed eligible for inclusion, 1541 (41.9%) initiated antiviral prophylaxis and 2136 (58.1%) did not. After overlap weighting, prophylactic antiviral therapy was significantly associated with lower risks of all-cause mortality (hazard ratio [HR] = 0.82; 95% CI = 0.70 to 0.96), cancer-related mortality (HR = 0.82; 95% CI = 0.69 to 0.97), and HBVr (HR = 0.49; 95% CI = 0.39 to 0.61) within 1 year. Consistent results were found across various subgroups and multiple sensitivity analyses.
Conclusions
Initiation of prophylactic antiviral therapy was associated with significant reductions in mortality and HBVr within 1 year in cancer patients with HBeAg-negative chronic HBV infection who received IST in real-world clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
ORCID-Profile: Sheng Nie, Licong Su, Zhixin Guo, Xin Xu, Guobao Wang
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
Zitieren
APA
Nie, S., Cao, L., Su, L., Zhou, S., Li, Y., Chen, R., Luo, F., Gao, Q., Lin, Y., Guo, Z., Xu, X., Wang, G., & CRDS Study Investigators (2025). Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf032
Vancouver
Nie S, Cao L, Su L, Zhou S, Li Y, Chen R, et al. Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf032
BibTeX
@article{Nie2025,
author = {Nie, Sheng and Cao, Lisha and Su, Licong and Zhou, Shiyu and Li, Yanqin and Chen, Ruixuan and Luo, Fan and Gao, Qi and Lin, Yuxin and Guo, Zhixin and Xu, Xin and Wang, Guobao and CRDS Study Investigators, CRDS Study Investigators},
title = {Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djaf032}
}
EUVIMED